Riordan, Lewis & Haden’s sale of Avella fetches about $325 mln

Riordan, Lewis & Haden, Avella Specialty Pharmacy, UnitedHealth Group, Drugs, medicine, pharmacy, private equity, merger, M&A,
Photo courtesy 4X-image/ iStock/Getty Images
Riordan, Lewis & Haden’s sale of Avella Specialty Pharmacy commanded an about $325 million valuation, two sources told Buyouts. The buyer is UnitedHealth Group, which quietly bought the specialty pharmacy company through the OptumRx segment of its Optum subsidiary. The ...

This content is available for Buyouts subscribers only. Request a free trial to get access for a limited period

If you already have an active Buyouts subscription, please sign in to view this article.